Pulmocide
PrivateLast Round
Series C
Extension
Dec 6, 2022
Total Funding Raised
$205.3M
Company Overview
Pulmocide is a biopharmaceutical company that specializes in the development of inhaled antifungal drugs aimed at treating acute and chronic respiratory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pulmocide Comparables
Compare Pulmocide with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| F2G | 82% | |
| Pulmatrix, Inc. | 81% | |
| Matinas BioPharma Holdings, Inc. | 71% | |
Pulmocide Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Dec 6, 2022 | ||||
| Grant | Dec 6, 2021 | ||||
| Series C | May 27, 2021 | ||||
| Series B | Mar 20, 2017 | ||||
| Series A | Nov 20, 2013 |
Key People
Founding team and executive leadership
Pulmocide Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pictet Group | Series C Extension |
| SV Health Investors | Series C, Series C Extension, Series B, Series A |
| IP Group | Series C, Series C Extension |
| F-Prime Capital | Series C, Series C Extension, Series B, Series A |
| Pictet Alternative Advisors | Series C Extension |
| Imperial Innovations | Series B |
| Imperial Innovations | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 6, 2022
Raised $52M led by Pictet Group and Vivo Capital.
- Dec 6, 2021
$4M raised from the Cystic Fibrosis Foundation.
Pulmocide Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Pulmocide's valuation, stock price, and market status.